Table 1 (abstract P063). Efficacy of SEC in ERA and JPsA pts
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
Variable | ERA | JPsA | ||||
|---|---|---|---|---|---|---|
TP1-Wk 12 | End of TP2* | Â | TP1-Wk 12 | End of TP2* | Â | |
SEC (N=52) | SEC (N=22) | PBO (N=22) | SEC (N=34) | SEC (N=15) | PBO (N=16) | |
JIA ACR30, % | 84.6 | 90.9 | 68.2 | 91.2 | 86.7 | 62.5 |
JIA ACR50, % | 78.8 | 81.8 | 68.2 | 91.2 | 73.3 | 56.3 |
JIA ACR70, % | 65.4 | 68.2 | 54.5 | 70.6 | 66.7 | 31.3 |
JIA ACR90, % | 32.7 | 45.5 | 50.0 | 47.1 | 60.0 | 25.0 |
JIA ACR100, % | 26.9 | 36.4 | 45.5 | 20.6 | 53.3 | 25.0 |
Inactive disease, % | 38.5 | 50.0 | 50.0 | 29.4 | 46.7 | 18.8 |
JADAS-27, mean (SD) change from BL | –9.6 (7.5) | –11.0 (8.9) | –7.6 (8.9) | –11.9 (6.7) | –11.5 (9.0) | –7.0 (7.2) |